| SCHEDULE OF NON CONTROLLING INTEREST |
SCHEDULE
OF NON CONTROLLING INTEREST
| | |
June 30, 2023 | | |
December 31, 2022 | |
| Net loss Subsidiary | |
$ | (121,063 | ) | |
$ | (817,151 | ) |
| Net loss attributable to the non-controlling interest | |
| 33,658 | | |
| 193,372 | |
| Net loss affecting Bioxytran | |
| (87,405 | ) | |
| (623,780 | ) |
| | |
| | | |
| | |
| Accumulated losses | |
| (3,574,358 | ) | |
| (3,594,287 | ) |
| Accumulated losses attributable to the non-controlling interest | |
| 785,236 | | |
| 751,578 | |
| Accumulated losses Bioxytran | |
| (2,789,122 | ) | |
| (2,842,709 | ) |
| | |
| | | |
| | |
| Net equity non-controlling interest | |
$ | (624,286 | ) | |
$ | (590,628 | ) |
|
SCHEDULE
OF NON CONTROLLING INTEREST
| | |
December 31, 2022 | | |
December 31, 2021 | |
| Net loss Subsidiary | |
| (817,151 | ) | |
| (2,089,253 | ) |
| Net loss attributable to the non-controlling interest | |
| 193,372 | | |
| 496,297 | |
| Net loss affecting Bioxytran | |
| (623,780 | ) | |
| (1,592,956 | ) |
| | |
| | | |
| | |
| Accumulated losses | |
| (3,594,287 | ) | |
| (2,777,135 | ) |
| Accumulated losses attributable to the non-controlling interest | |
| 751,578 | | |
| 558,206 | |
| Accumulated losses affecting Bioxytran | |
| (2,842,709 | ) | |
| (2,218,929 | ) |
| | |
| | | |
| | |
| Net equity non-controlling interest | |
| (590,628 | ) | |
| (397,256 | ) |
|